"We are expecting revenues of up to Rs 2,500 crore in the next fiscal FY18 maintaining a compounded annual growth rate (CAGR) of over 20 per cent year-on-year," Himalaya Drug Company CEO Philipe Haydon told PTI.
At present, Himalaya's biggest vertical is personal care contributing 42 per cent to total sales, followed by pharmaceutical 32 per cent, baby care 15 per cent, animal health 5 per cent and wellness 5 per cent, he added.
"We have just launched mothercare products with the launch of 4 products followed by at least 8 products in next one and one and half years. We expect this segment to contribute to 5 to 6 per cent to our revenues in next two years," Haydon said.
The company is aiming to expand presence in all the verticals it is in, he added.
As part of the expansion process the company is also looking to add to its workforce which is around 9,000 to 10,000 at present.
"We plan to add at least a 1,000 people during the next fiscal in all the verticals as we increase our verticals and distribution network that we are in," Haydon said.
The company, which sells herbal products, is also enhancing its research in order to tap into the knowledge of ancient Indian medicinal practice and has developed a large research and development facility.
"Our strong focus on innovation and rigorous research has helped us develop more than 300 products spanning 7 divisions and we will continue to explore the potential of Ayurveda in improving the quality of life," Himalaya Drug Company Chief Scientific Officer Rangesh Paramesh said.
Himalaya has spent years studying the therapeutic benefits of herbs to use in its products and every product is created following stringent standards of safety, efficacy and quality control, he added.
It has a range of over 300 healthcare and personal care products including popular brands like Liv 52, Cystone, and Bonnisan. The company currently operates in over 90 countries.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.